Cornerstone Capital Management Holdings’s Alaunos Therapeutics TCRT Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$441K	Buy	712 +179	+34%	+$129K	﹤0.01%	1027
2017 Q3	$490K	Hold	533	–	–	﹤0.01%	1057
2017 Q2	$496K	Sell	533 -4	-0.7%	-$3.92K	﹤0.01%	1036
2017 Q1	$510K	Buy	+537	New	+$500K	﹤0.01%	1058
2016 Q2	–	Sell	-13	Closed	-$15K	–	1486
2016 Q1	$15K	Sell	13 -2	-13%	-$2.05K	﹤0.01%	1455
2015 Q4	$18K	Sell	15 -20	-57%	-$33.1K	﹤0.01%	1413
2015 Q3	$47K	Buy	35 +3	+9%	+$4.95K	﹤0.01%	1410
2015 Q2	$58K	Buy	32 +21	+191%	+$32.6K	﹤0.01%	1345
2015 Q1	$17K	Buy	+11	New	+$16.3K	﹤0.01%	1346

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cornerstone Capital Management Holdings's TCRT Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Alaunos Therapeutics (TCRT) stake by 34% in Q4 2017, buying an estimated $129K and bringing the position to 712 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

Cornerstone Capital Management Holdings first reported a position in TCRT in Q1 2015 and has held it in 9 quarters since. The position peaked at $510K in Q1 2017. 128 funds tracked by Wall St. Rank hold TCRT as of Q4 2017.

Cornerstone Capital Management Holdings held 712 shares of Alaunos Therapeutics worth $441K as of Q4 2017.
Cornerstone Capital Management Holdings bought 179 Alaunos Therapeutics shares in Q4 2017, an estimated $129K.
Alaunos Therapeutics made up ﹤0.01% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #1027 holding.
Cornerstone Capital Management Holdings first reported a position in Alaunos Therapeutics in Q1 2015 and has held it in 9 quarters since.
Cornerstone Capital Management Holdings's Alaunos Therapeutics position peaked at $510K in Q1 2017.
128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.